(Q37147777)

18 August 2017

1 reference

title

Current issues in ER and HER2 testing by IHC in breast cancer (English)

1 reference

18 August 2017

1 reference

Allen M Gown

1

1 reference

18 August 2017

publication date

1 May 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

21 Suppl 2

1 reference

18 August 2017

page(s)

S8-S15

1 reference

Prognostic value of estrogen receptors in primary breast cancer

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

Biologic significance of quantitative estrogen receptor immunohistochemical assay by image analysis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

Objective measurement of breast cancer oestrogen receptor status through digital image analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

Dynamic and modern: bringing the ethics of phase I trials up to date.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

HER-2 testing in breast cancer using parallel tissue-based methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

Immunohistochemical Detection Using the New Rabbit Monoclonal Antibody SP1 of Estrogen Receptor in Breast Cancer Is Superior to Mouse Monoclonal Antibody 1D5 in Predicting Survival

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp gamma in frozen sections or cytosol-based ligand-binding assays

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

The value of estrogen and progesterone receptors in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

The evaluation of estrogen receptor in primary breast carcinoma by computer-assisted image analysis

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

Estrogen receptor testing of breast cancer in current clinical practice: what's the question?

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

HER-2/neu oncogene protein and prognosis in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

No rational theory for drug pricing

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

Concordance between central and local laboratory HER2 testing from a community-based clinical study

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

Increased HER2 with U.S. Food and Drug Administration-approved antibody

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.34

7 January 2021

10.1038/MODPATHOL.2008.34

Identifiers

DOI

1 reference

18 August 2017

1 reference